Results 11 to 20 of about 52,753 (266)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations

Frontiers in Pharmacology, 2020
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for ...
Sabina Mugusi, Sabina Mugusi, Abiy Habtewold, Eliford Ngaimisi, Wondwossen Amogne, Getnet Yimer, Omary Minzi, Eyasu Makonnen, Eyasu Makonnen, Christopher Sudfeld, Jürgen Burhenne, Eleni Aklillu   +11 more
doaj   +2 more sources

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z.   +4 more
europepmc   +2 more sources

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle‐mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable.
Al-Amiry Santos LG, Polak S, Yeo KR.
europepmc   +2 more sources

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.

Clinical Infectious Diseases, 2022
Participants randomised to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks ...
Bronwyn Bosch, Godspower Akpomiemie, N. Chandiwana, Simiso M Sokhela, Andrew Hill, K. McCann, A. Qavi, Manya Mirchandani, W. Venter   +8 more
semanticscholar   +1 more source

Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.

Clinical Infectious Diseases, 2022
BACKGROUND Higher doses of rifampicin may improve treatment outcomes and reduce the duration of TB therapy, but drug-drug interactions with anti-retroviral therapy (ART) and safety in people living with HIV have not been evaluated.
C. Sekaggya-Wiltshire, R. Nabisere, J. Musaazi, B. Otaalo, F. Aber, L. Alinaitwe, J. Nampala, Letisha Najjemba, Allan Buzibye, Denis Omali, Kamunkhwala Gausi, Allan Kengo, M. Lamorde, R. Aarnoutse, P. Denti, K. Dooley, D. Sloan   +16 more
semanticscholar   +1 more source

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy

British Journal of Clinical Pharmacology, 2021
Dolutegravir is associated with more weight gain than efavirenz in people starting antiretroviral therapy (ART). We investigated the concentration–response relationships of efavirenz and dolutegravir with weight gain. We determined concentration–response
Rulan Griesel, A. Kawuma, R. Wasmann, Simiso M Sokhela, Godspower Akpomiemie, Wd Francois Venter, L. Wiesner, P. Denti, P. Sinxadi, G. Maartens   +9 more
semanticscholar   +1 more source

Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus

Drug Development and Industrial Pharmacy, 2016
Zênia Maria Maciel Lavra, Davi Pereira de Santana, Maria Inês Ré   +2 more
openalex   +3 more sources

Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

Biomedicines, 2022
Drug-induced liver injury (DILI) constitutes a clinical challenge due to the incomplete characterization of the mechanisms involved and potential risk factors.
Fernando Alegre, Alberto Martí-Rodrigo, Miriam Polo, Dolores Ortiz-Masiá, Celia Bañuls, Marcello Pinti, Ángeles Álvarez, Nadezda Apostolova, Juan V. Esplugues, Ana Blas-García   +9 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

Clinical Infectious Diseases, 2020
Background Dolutegravir is associated with more weight gain than efavirenz. Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency
Rulan Griesel, G. Maartens, M. Chirehwa, Simiso M Sokhela, Godspower Akpomiemie, Michelle A. Moorhouse, F. Venter, P. Sinxadi   +7 more
semanticscholar   +1 more source